FindTrial
Sign In

Genotyping of carbapenemase enzymes produced by CRE and Aztreonam Ceftazidime Avibactam synergy testing for MBL producers

Genotyping of Carbapenem resistant Enterobacterales and Aztreonam and ceftazidime/ avibactam synergy testing against MBL producing Enterobacterales in a Tertiary Cancer Care Centre, Visakhapatnam. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/04/085861
Enrollment
170
Registered
2025-04-28
Start date
Unknown
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B962- Escherichia coli [E. coli ] as thecause of diseases classified elsewhere

Interventions

Intervention1: Nil: Nil

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: All Carbapenem-resistant Enterobacterale isolates from clinical specimens, including pus, urine, body fluids, sputum, and blood samples, received in the microbiology laboratory for culture and sensitivity testing

Exclusion criteria

Exclusion criteria: Carbapenem resistant Gram-negative bacteria other than Enterobacterales are excluded

Design outcomes

Primary

MeasureTime frame
To determine the prevalence of carbapenemase production among the Enterobacterale isolates from clinical specimens received for routine culture and sensitivity in Dept. of MicrobiologyTimepoint: 18 Months—

Secondary

MeasureTime frame
2. To detect different genes responsible for carbapenemase production among Enterobacterales 3. To evaluate the synergy of ceftazidime/ avibactam - aztreonam combination on the confirmed MBL producing Enterobacterales in vitroTimepoint: 18 Months—

Countries

India

Contacts

Public ContactDr Himabindu Vennelaganti

Homi Bhabha Cancer Hospital and Research Centre

himabindu.v2@gmail.com9618938168

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026